TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > Our Services > Biopharmaceuticals

Biopharmaceuticals

Established Biopharma Regulatory Experts

PharmaLex have an established and skilled multidisciplinary team of regulatory experts to support CMC, non-clinical and clinical areas.

Our biopharmaceutical experts understand the importance of developing therapies for unmet needs, as well as the pressure of getting that drug from pipeline to market quicker. We also recognize that no two companies are the same, and therefore focus our efforts on providing flexible, tailor-made solutions to ensure every aspect of your drug development lifecycle is carefully planned and executed.

With over 75 CMC consultants across the globe, PharmaLex has substantial CMC expertise across all areas. We are able to offer an integrated solution combining the scientific, technological, non-clinical, clinical and regulatory expertise with our broad global project experience to meet your specific needs, from discovery to licensing and post-approval.

If you would like to register your interest in a training session or strategy workshops (remote or face-to-face), please contact us using the link below.

Want to find out more?

PharmaLex. Confidence beyond compliance.

Contact us for more information

We offer support in the following areas:

  • Development and regulatory strategy considering regional requirements (e.g. US, EU, Canada, Japan, Emerging Markets)
  • Gap Analysis / Due diligence
  • Technical writing and compilation of regulatory documents
  • Scientific advice and other health agency meetings
  • Risk assessment
  • Preparation of TPP
  • Comparability exercises
  • General ‘troubleshooting’, including investigations and root cause analysis and
    support for CAPA
  • Deviation and change control preparation / review
  • Method / process validation
  • Process characterization
  • Project management

Related News

PharmaLex expands technology-enabled solution portfolio with integration of software platforms
PharmaLex expands technology-enabled solution portfolio with integration of software platforms
30th November 2021
TGA looks to comparable overseas regulators to speed up access to new medicines
TGA looks to comparable overseas regulators to speed up access to new medicines
15th November 2021
Can a robust QMS help you achieve customer satisfaction?
Can a robust QMS help you achieve customer satisfaction?
22nd September 2021

Related Resources

Thought Leadership

  • Supporting M&As in the pharmaceutical/biopharmaceutical industry
  • Drug Development Decisions

Fact Flyers

  • Veeva Vault RIM Implementation
  • ATMP Quick Links and Guidelines
  • Biosimilar Quick Links and Guidelines
  • Regulatory Compliance - CMC Implementation
  • Biopharmaceuticals CMC
  • Chemistry, Manufacturing and Control (CMC)

Case Studies

  • Biosimilarity assessment on multiple CQAs
  • Dendritic cell vaccine (oncology)
  • Regulatory CMC Compliance reduced risk
  • Type C Meeting
  • End of Phase-2 meeting
  • Veeva Vault RIM Implementation
  • Consultancy and eCTD submission support for master files
  • Global CMC responsibility during portfolio integration
  • Lifecycle management for drug products
  • Regulatory CMC compliance reduced workload by 20-25%
  • Due diligence for medicinal product documentation
  • Strategy and delivery of global biosimilar development program

White Papers

  • Together Beyond COVID-19 - A Look at the Future
  • The Challenges of Achieving and Maintaining CMC Compliance
  • Differing CMC requirements: US and EU

Webinars

  • Introduction to Bayesian Methodologies in CMC
  • Biotech Drug Development Challenges and Case Studies (CMC)
  • Overview of the biotech drug development pathway
  • An Overview to Non clinical testing: why? when? what?
  • Achieving and maintaining REG CMC Compliance
  • Regulatory Landscape for Tissue, Cell and Gene Therapy
  • Optimize your biosimilar development strategy

Infographics

  • Biosimilar Development

Video & Animation

  • Using Bayesian Statistics for Clinical Research

Related Services

  • Biopharma
  • CMC Services
  • Global End-to-End Outsourcing
  • GxP Services
  • INTEGRATED PRODUCT DEVELOPMENT (IPD)
  • Mergers and Acquisitions (M&A) Transfers

Key members of our team

Martin Mewies

Associate Director, Regulatory CMC Biologics at PharmaLex

Martin has 25 years of experience in protein biochemistry, with 16 years in biologics CMC / Regulatory, including new product development, MAA submissions, life-cycle management, capital projects and project management.

Swen Grein
Swen Grein

Team Lead, Regulatory CMC at PharmaLex

Swen has a strong scientific background in protein biochemistry and molecular biology. He has more than 20 years of biotech and biopharma industry experience, including process and analytical development, technology transfer, CMC regulatory affairs and quality management.

CMC Biotech Q & A

Some of the most common types of questions we are asked are summarized to the right. In most cases for these products there is no single correct answer for all programs and many of the responses are completed on a-case-by-case basis based on the type of product and specific scenario, therefore we have summarized our general approach to responding to these queries.

Minimum requirements

What are the minimal requirements we need to ensure are in place for our program, for the stage of development we are in – to be sure to meet any critical regulatory requirements but are still able to run our program as lean as possible?

This is one of the most common queries we receive in one form or another. To provide a suitably comprehensive response we would typically conduct a multidisciplinary (CMC, nonclinical and clinical) gap analysis of the available documentation and plans to identify the most critical gaps in the program, highlighting the greatest risks to achieving the next project milestone.

Based on the gap analysis, we would then provide appropriate recommended actions/options for the identified gaps.

In order to ensure the program is as lean as possible, we may recommend approaches that are not in accordance with regulatory guidance’s but scientifically justified, in these cases we will advise that these are agreed in appropriate agency scientific advice discussions before implementing.

Target Product Profile (TPP)

How do we prepare our TPP?

The target product profile (TPP) is useful to put in place early in development, although can also be established later in the program. We view this as a valuable multidisciplinary strategic set of targets for your product outlining the regulatory goals (included intended markets), presentation/indication, envisaged posology, clinical, nonclinical and quality expectations. It allows you to keep focussed on the end targets during development and to keep the project within scope during development.

There are a number of options with how to approach this, but we have example templates of the basic requirements which can be tailored for your program. The TPP is not set in stone and should routinely reviewed as part of your development program.

Critical Quality Attributes

How do we define CQAs?

A critical quality attribute (CQA) is a physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality (ICH Q8 (R2)).

We normally assign CQAs by using our CQA assignment tool, which assesses the impact of each quality attribute on bioactivity, immunogenicity, PK/PD and safety. This activity normally involves details literature searches, review of available characterisation and CMC data alongside input from nonclinical and clinical teams.

Once the CQAs are established they can be monitored during the program and support the impact assessment of any changes/steps in the manufacturing process. The defined list of CQAs should be routinely reviewed and updated as more data is generated on the product and available methodologies.

Critical Process Parameters

How do we define CPPs?

A critical process parameter (CPP) is a process parameter whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality (ICH Q8 (R2)).

A common approach for assigning CPPs is using a failure mode effect analysis (FMEA). This is a risk-based assessment of the manufacturing process unit operations with regards to the potential severity of failure and likely hood of occurrence and ability to detect the occurrence. Various scoring guides are available and can be used, however it is important to ensure the overall scoring system allows for a ‘sense check’ that has provision for technical scientifically sound justifications to be used for the final assignment.

The final CPP assignment can be used to define process characterization requirements and eventually the acceptance criteria for process performance qualification.

Biosimilar – number of lots

How many lots required for biosimilarity assessment?

This is the most common question we are asked by biosimilar developers. And unfortunately no single number can be given for all biosimilars in development. From a guidance point of view this has not yet been fixed, and it is likely there will be no fixed number recommended by Agencies.

The final number of reference product lots required will need to be able to account for the potential variability in manufacture and age of the reference product. In addition one of the contributing factors is the complexity of the molecule under development. Of note, if any shifts are observed in the data set, this may increase the number of lots required to be sure sufficient data from at least one consistent data set is available.

It will be of course also important to consider regional reference product requirements and material requirements to support the analytical/nonclinical/clinical studies, including any 3-way pairwise bridging studies.

The final number of lots of the biosimilar drug substance/drug product may potentially be less that the number of reference product lots, but will also need to allow for potential variability in the manufacturing process and the final data set should be amenable to statistical evaluation, where applicable.

The PharmaLex family includes a team of biotech statistical experts (PharmaLex Arlenda) who support such statistical analysis and can ‘translate’ the statistical requirements to the development teams.

The final approach to biosimilarity assessment should be agreed upfront with the relevant agencies.

Comparability

How should we approach a comparability assessment for our specific change?

Historically the traditional approach of full release and characterization on three lots before and after the change was taken. However, we recommend a risk based approach to omit unnecessary testing but to ensure high risks are evaluated. In addition, depending on your product and specific change we may recommend different approaches.

For example in the case of a change to manufacturing process step the plan will be different for a live attenuated vaccine, Chimeric antigen T cell receptor (CAR-T) product or a monoclonal antibody (mAb) product. These products will have different levels of process characterization and understanding and the level of specific methods that may correlate the impact of a quality change to efficacy or safety will be different.

Based on the available information we would recommend an approach to comparability assessment and depending on the approach recommended, we may also advice discussion with the relevant agencies regarding acceptability.

Risk Assessment

What is the most suitable approach for a risk assessment for our particular CMC scenario?

There are various approaches to risk assessment, a number of which are described in ICH Q9. Different tools are used for different scenarios and include the simpler risk ranking and filtering or more detailed FMEA. These evaluations can be supported with process maps/flow charts/checklists/statistical tools.

We would advise a risk assessment approach depending on the scenario with simpler processes for early and simple changes or more detailed comprehensive process for later and more complex changes.

Minimum Controls Required

What minimum controls and characterisation data are required for our process to support our first in human study?

In addition to the regional GMP requirements, you need to be able to demonstrate that your manufacturing process is reasonably well controlled.

Your specifications maybe wider than you would expect for later in development but must be suitably justified for your drug substance, drug product and any relevant intermediates.

Your test methods must be demonstrated to be ‘fit for purpose’.

Any concerns regarding impurities (process and product related) should be identified appropriately characterized and assessed as a low risk to safety.

Product stability for any in-use preparation and the duration of your planned study must be established based on real time data, you may be able to justify this using representative development lots.

Out of Specification (OOS)

What is the impact of this OOS stability result on our clinical batch shelf life assignment?

Out of specification (OOS) results during stability must be appropriately investigated before they are confirmed as OOS results. Even if all testing is outsourced to a contractor the sponsor is responsible for ensuring they understand the conclusions and the implications of the results.

Such information should be assessed immediately as depending on the result that is OOS and the timepoint the test was conducted, the shelf life of the product may be affected and this may also impact an ongoing clinical study.

CMC for BLA and MAA

Now we have reached pre-BLA / MAA stage, what particular CMC activities should we focus on to support filing/submission?

There are a number of pre-BLA / MAA activities that should be completed prior to submission and filing to avoid delays and review questions.

At PharmaLex we would conduct a gap analysis of the package available to identify a list of risk ranked requirements for successful BLA / MAA submissions. A few examples of the common CMC items identified from this review includes: compendial / GMP compliance, forced degradation studies, data-based justification of specifications, reference standard establishment and extractable and leachable studies.

What our clients say

Pharmalex provided the resources we needed to compile Investigational Medicinal Product Dossiers for our biological products. The dossiers were delivered on time with the trusted quality we expected

Small US Biopharmaceutical Company
Sr Director Regulatory Affairs CMC

Provided honest feedback and collaborative working solutions to obstacles

South Korea based medium sized company
Manager
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
4 May

Francesco Lanucara’s latest article discusses how important it is to provide clear information and keep up with regulatory guidelines.

Read the article here: https://lnkd.in/dFt4KBVy

For this and more articles subscribe to our newsletter.
#cellandgene #lifescience #cmc #ilap

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • They are available when we need to talk to them despite any time zone differentials

    Japan based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for